5tr8
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==Crystal structure of vaccine-elicited pan- influenza H1N1 neutralizing murine antibody 441D6.== | ==Crystal structure of vaccine-elicited pan- influenza H1N1 neutralizing murine antibody 441D6.== | ||
| - | <StructureSection load='5tr8' size='340' side='right' caption='[[5tr8]], [[Resolution|resolution]] 2.01Å' scene=''> | + | <StructureSection load='5tr8' size='340' side='right'caption='[[5tr8]], [[Resolution|resolution]] 2.01Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[5tr8]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/ | + | <table><tr><td colspan='2'>[[5tr8]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5TR8 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5TR8 FirstGlance]. <br> |
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NI:NICKEL+(II)+ION'>NI</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NI:NICKEL+(II)+ION'>NI</scene></td></tr> | ||
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">HC ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id= | + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">HC ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10090 LK3 transgenic mice])</td></tr> |
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5tr8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5tr8 OCA], [http://pdbe.org/5tr8 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5tr8 RCSB], [http://www.ebi.ac.uk/pdbsum/5tr8 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5tr8 ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5tr8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5tr8 OCA], [http://pdbe.org/5tr8 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5tr8 RCSB], [http://www.ebi.ac.uk/pdbsum/5tr8 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5tr8 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | The present vaccine against influenza virus has the inevitable risk of antigenic discordance between the vaccine and the circulating strains, which diminishes vaccine efficacy. This necessitates new approaches that provide broader protection against influenza. Here we designed a vaccine using the hypervariable receptor-binding domain (RBD) of viral hemagglutinin displayed on a nanoparticle (np) able to elicit antibody responses that neutralize H1N1 influenza viruses spanning over 90 years. Co-display of RBDs from multiple strains across time, so that the adjacent RBDs are heterotypic, provides an avidity advantage to cross-reactive B cells. Immunization with the mosaic RBD-np elicited broader antibody responses than those induced by an admixture of nanoparticles encompassing the same set of RBDs as separate homotypic arrays. Furthermore, we identified a broadly neutralizing monoclonal antibody in a mouse immunized with mosaic RBD-np. The mosaic antigen array signifies a unique approach that subverts monotypic immunodominance and allows otherwise subdominant cross-reactive B cell responses to emerge. | ||
| + | |||
| + | Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses.,Kanekiyo M, Joyce MG, Gillespie RA, Gallagher JR, Andrews SF, Yassine HM, Wheatley AK, Fisher BE, Ambrozak DR, Creanga A, Leung K, Yang ES, Boyoglu-Barnum S, Georgiev IS, Tsybovsky Y, Prabhakaran MS, Andersen H, Kong WP, Baxa U, Zephir KL, Ledgerwood JE, Koup RA, Kwong PD, Harris AK, McDermott AB, Mascola JR, Graham BS Nat Immunol. 2019 Mar;20(3):362-372. doi: 10.1038/s41590-018-0305-x. Epub 2019, Feb 11. PMID:30742080<ref>PMID:30742080</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 5tr8" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| - | [[Category: | + | [[Category: Large Structures]] |
| + | [[Category: Lk3 transgenic mice]] | ||
[[Category: Graham, B S]] | [[Category: Graham, B S]] | ||
[[Category: Joyce, M G]] | [[Category: Joyce, M G]] | ||
Revision as of 06:11, 7 August 2019
Crystal structure of vaccine-elicited pan- influenza H1N1 neutralizing murine antibody 441D6.
| |||||||||||
